Absci: Compelling AI Biotech Story, but Weak Fundamentals and Bearish Structure
Absci (NASDAQ:ABSI) presents a classic disconnect between its compelling AI biotech narrative and its weak financial fundamentals, characterized by declining revenue, persistent losses, and inconsistent earnings. The stock remains in a long-term downtrend despite short-term consolidation, with significant upside potential contingent on catalysts like strong clinical data from ABS-201 or new strategic partnerships. Given the high financial and technical risks, the article recommends a speculative HOLD.
We Think Absci (NASDAQ:ABSI) Needs To Drive Business Growth Carefully
This article analyzes Absci's financial health, specifically its cash burn rate and cash runway. As of December 2025, Absci had a cash runway of about 18 months, with a cash burn of US$94m and cash reserves of US$144m. The article raises concerns about increasing cash burn (up 29% year-on-year) and declining operating revenue (down 38%) and suggests that future equity raises could lead to significant shareholder dilution.
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9
JonesTrading analyst Debanjana Chatterjee has reiterated a Buy rating for Absci Corp (ABSI.US) and maintained a target price of $9. This rating is based on the analyst's track record of a 58.6% success rate and an average return of 38.2% over the past year, according to TipRanks data. The article also provides a disclaimer that this information is for educational purposes only and not investment advice.
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9
JonesTrading has reiterated its Buy rating on Absci Corp (ABSI.US), maintaining a target price of $9. This indicates continued confidence in the company's prospects by the investment firm.
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7
Needham has reiterated its Buy rating for Absci Corp (ABSI.US), keeping the target price at $7. This indicates a continued positive outlook on the company's stock performance from the analyst firm.
Absci outlines $25B annual market potential for ABS-201 in AGA and advances endometriosis clinical program
Absci has identified a significant market opportunity for its drug ABS-201, estimating a $25 billion annual market for androgenetic alopecia (AGA). The company and its partners are also advancing their clinical program for endometriosis, signaling a dual focus on innovative disease treatments and market expansion.
Absci Corp | 8-K: Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results - moomoo
This article references an 8-K filing from Absci Corp detailing its business updates and financial and operating results for the fourth quarter and full year 2025. The filing would contain comprehensive information on the company's performance and strategic developments during that period.
Absci (NASDAQ: ABSI) deepens 2025 loss while pushing ABS-201 toward key data
Absci Corporation reported a widening net loss in 2025 due to increased R&D spending, despite a decrease in revenue. The company is advancing its lead drug candidate, ABS-201, through Phase 1/2a trials for androgenetic alopecia with favorable early safety data, and plans to initiate a Phase 2 trial for endometriosis in late 2026. Absci expects its current cash reserves of $144.3 million to fund operations into the first half of 2028, supporting its AI-driven drug discovery pipeline.
Absci files $400M mixed securities shelf
Absci has filed a mixed securities shelf valued at $400 million. This financial move allows the company flexibility in future fundraising through various types of securities.
Vanguard affiliates to report separately as ABSI holdings shift (ABSI)
A recent Schedule 13G/A filing indicates that The Vanguard Group now reports zero beneficial ownership of Absci Corp (ABSI) common stock, representing 0% of the company. This change is due to an internal realignment within Vanguard, where certain subsidiaries will now report their holdings separately, in accordance with SEC Release No. 34-39538. This filing is a procedural compliance disclosure and does not signify a sale or change in economic ownership by Vanguard as a whole, but rather a disaggregation of reporting.
Absci files $400M mixed securities shelf
Absci has filed a mixed securities shelf valued at $400 million. This financial move allows the company to offer various types of securities over time, providing flexibility for future fundraising needs.
Absci: Downgrade To 'Hold' As ABS-101 On Back Burner And Pivot To ABS-201 (NASDAQ:ABSI)
Absci Corporation has been downgraded to 'Hold' because its lead candidate, ABS-101, failed to demonstrate sufficient differentiation against existing TL1A treatments, leading to its internal development being halted. The company is now shifting its focus to ABS-201 for androgenetic alopecia, but significant efficacy data is not expected until late 2026 or early 2027. Despite a cash runway extending into the first half of 2028, competitive threats and clinical uncertainties pose substantial risks.
Absci Corp reports results for the quarter ended December 31 - Earnings Summary
Absci Corp has reported its earnings summary for the quarter that ended on December 31. The article, provided by Refinitiv and Reuters, is a brief update on the company's financial performance during this period. More detailed information often requires logging in or creating an account.
Absci Corporation (ABSI) reports Q4 loss, misses revenue estimates
This article reports that Absci Corporation (ABSI) announced a Q4 loss, missing analyst revenue estimates. The financial performance indicators suggest a challenging quarter for the company. Further details on the specific financial figures and future outlook were not provided in the prompt.
Absci Corp’s 2025 Q4 Call: FDA Delays, Oncology Partnership Shifts, and ABS-201 Timeline Contradictions
Absci Corp's Q4 2025 earnings call highlighted promising early safety data for ABS-201 in its Phase I/IIa trial and expansion into endometriosis. The company reported a strong financial position, over $144 million in cash, and a strategic focus on ABS-201 while seeking partnerships for other assets. However, the call also revealed contradictions regarding FDA engagement for Phase III trials, partnering strategies for oncology programs, and ABS-201 formulation and clinical design, potentially impacting investor confidence and future timelines.
Absci Corp’s 2025 Q4 Call: FDA Delays, Oncology Partnership Shifts, and ABS-201 Timeline Contradictions
Absci Corp's 2025 Q4 earnings call revealed promising safety data for ABS-201 in clinical trials and an expansion into endometriosis as a second major indication. Despite a positive overall tone from management, the article highlights several inconsistencies regarding FDA engagement for Phase III design, partnering strategies for other pipeline assets (ABS-101, ABS-301, ABS-501), and the timeline for ABS-201's clinical trial readouts, potentially causing investor confusion. The company reported $700,000 in revenue for Q4 2025 and has enough cash to fund operations into the first half of 2028.
Earnings call transcript: Absci’s Q4 2025 earnings miss forecasts, stock dips
Absci Corporation reported a significant miss on its Q4 2025 earnings, with EPS of -$0.20 against a forecast of -$0.18, and revenue of $700,000 against an anticipated $1.38 million, leading to a 1.54% stock dip. Despite these financial setbacks and increased R&D expenses, the company maintains a strong cash position, projecting operations funding into 2028, and highlighted promising progress in its clinical pipeline, particularly for the ABS-201 program in androgenetic alopecia and endometriosis. Absci aims to leverage its AI design platform for accelerated drug development, focusing on high-ROI programs and strategic partnerships.
Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates
Absci Corporation (ABSI) reported a Q4 loss of $0.23 per share, missing the Zacks Consensus Estimate of a $0.16 loss, and revenues of $0.65 million, falling short of estimates by 82.15%. The company has not beaten consensus revenue estimates in the last four quarters, and its shares have declined by 16.1% year-to-date. The stock currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
Absci Corporation reported its fourth quarter and full year 2025 financial and operating results, highlighting progress in its clinical trials and AI-driven drug discovery. The company successfully dosed the first three cohorts of its ABS-201 HEADLINE trial for androgenetic alopecia and endometriosis, showing favorable safety data and efficacy in stimulating hair growth in ex vivo human data. Absci also announced the appointment of Ransi Somaratne as Chief Medical Officer and stated that its current cash reserves are sufficient to fund operations into the first half of 2028.
AbSci Corp options imply 13.4% move in share price post-earnings
Options trading in AbSci Corp (ABSI) suggests a significant 13.4% move in its share price following its upcoming earnings release. Call options are leading puts with a 15:2 ratio, indicating bullish sentiment. This anticipated movement, estimated at 40 cents, is notably higher than the historical median move of 4.8% over the last eight quarters.
Absci taps Yale, Mayo experts for non-hormonal endometriosis drug
Absci has formed an Endometriosis Advisory Board with leading experts from institutions like Yale, UCSF, Duke, and the Mayo Clinic to guide the clinical development of ABS-201. This non-hormonal, anti-prolactin receptor antibody aims to treat endometriosis by targeting inflammation and lesion survival without impacting ovulation or fertility. Absci anticipates a Phase 2 study initiation in Q4 2026, with an interim data readout expected in H2 2027.
ABSI PE Ratio & Valuation, Is ABSI Overvalued
This article analyzes the valuation of Absci Corp (ABSI), stating that its current forward P/S ratio of 34.79 places it in the "Fair zone" compared to its five-year average. The fair price range for ABSI is estimated between $0.31 to $5.84 based on relative valuation. However, ABSI's P/S ratio is significantly higher than its competitors, raising questions about the sustainability of its premium given a robust revenue growth of -77.78%.
ABSI Absci Corporation NASDAQ $2.86 on 19 Mar 2026: earnings Mar 24 could shift targets
Absci Corporation (ABSI) stock is trading at $2.86 on NASDAQ ahead of its earnings report on March 24, 2026. The article details the company's financial performance, analyst ratings, and technical signals, highlighting the potential for significant stock movement based on the upcoming earnings. While analysts project substantial upside with a consensus target of $7.66, Meyka AI provides a more conservative forecast of $2.55, assigning a "HOLD" rating due to growth potential and execution risks.
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7
Needham analyst Gil Blum has reiterated a Buy rating for Absci Corp (ABSI.US) and maintained a target price of $7. According to TipRanks data, Blum has a 38.8% success rate and an 8.0% average return over the past year. This information is intended for educational purposes and not as investment advice.
Needham Reiterates Buy Rating for Absci (ABSI) with Unchanged Pr
Needham has reiterated its "Buy" rating for Absci (ABSI), maintaining a price target of $7.00, indicating continued confidence in the stock. This comes amidst other analyst ratings, both reaffirming and adjusting price targets for Absci. With an average target price of $8.05 from 7 analysts, the stock shows a potential upside of 165.54% from its current price of $3.03, and an "Outperform" status based on consensus recommendations.
Absci (NASDAQ:ABSI) Given Buy Rating at Needham & Company LLC
Needham & Company LLC reiterated a "buy" rating for Absci (NASDAQ:ABSI) on Wednesday, setting a $7.00 price target, which implies a 131.02% upside. The company's stock generally holds a "Moderate Buy" consensus rating from analysts, with insider activity showing both sales by the CEO and a significant purchase by another insider. Institutional investors, including State Street, ARK, and Price T. Rowe, have also notably increased their stakes in the AI biotech firm.
Heights Capital Management Inc. Makes New Investment in Absci Corporation $ABSI
Heights Capital Management Inc. has acquired a new stake of 2,000,440 shares in Absci Corporation (NASDAQ:ABSI) during the third quarter, valued at approximately $6.08 million. This investment makes Absci 1.7% of Heights Capital Management's portfolio, with the firm now owning roughly 1.33% of Absci. Other institutional investors, including ARK Investment Management LLC, have also increased their holdings, contributing to hedge funds and institutional investors owning 52.05% of the stock.
Absci Corporation (NASDAQ:ABSI) Receives Average Rating of "Moderate Buy" from Analysts
Absci Corporation (NASDAQ:ABSI) has received a "Moderate Buy" consensus rating from seven brokerages, with an average 12-month price target of $7.66. Insider activity shows CEO Sean McClain selling shares while insider Andreas Busch purchased a significant amount, and institutional investors like ARK and Vanguard have increased their stakes. The stock is currently trading near $3.03, up 21.2%, with a market cap of approximately $456 million.
Absci (ABSI) to Release Quarterly Earnings on Tuesday
Absci (NASDAQ:ABSI) is scheduled to release its Q4 2025 earnings after the market closes on Tuesday, March 24, 2026, with analysts expecting a loss of $0.16 per share and revenue of $1.381 million. The article notes recent insider trading, with Andreas Busch increasing his stake while CEO Sean McClain sold some shares. Absci currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $7.66.
Absci (NASDAQ: ABSI) CFO receives new RSU and stock option awards
Absci Corp's CFO, Zachariah Jonasson, received routine equity compensation including 135,400 restricted stock units and stock options for 534,400 shares, with an exercise price of $2.80. These awards vest in three equal annual installments starting March 1, 2027. Additionally, 10,848 shares were withheld to cover tax obligations from RSU vesting, which was not a discretionary trade.
Absci (NASDAQ: ABSI) CEO granted 2M+ equity units and has shares withheld for taxes
Absci Corp's CEO, Sean McClain, received significant equity compensation, including 406,200 restricted stock units and stock options for 1,603,200 shares at an exercise price of $2.80, both vesting in three annual installments starting March 1, 2027. Additionally, 25,316 shares were withheld to cover tax obligations from RSU vesting, a non-discretionary transaction. Following these transactions, McClain directly holds 8,715,451 shares of Common Stock.
Absci (NASDAQ: ABSI) SVP Bedrick gets RSUs, options and tax withholding
Absci Corp's SVP and Chief Accounting Officer, Todd Bedrick, reported receiving routine equity compensation grants consisting of 49,600 restricted stock units and options for 195,900 shares, both vesting over three years starting March 1, 2027. Additionally, 5,282 shares were withheld to cover tax obligations related to the vesting of RSUs, which was not a discretionary market sale. This Form 4/A also corrected the expiration date of the previously reported options.
Absci (ABSI) innovation chief buys 100K shares at $2.29 each
Absci Corp's Chief Innovation Officer, Andreas Busch, purchased 100,000 shares of company stock at $2.29 each on March 12, 2026. This open-market transaction increased his direct ownership to 421,446 shares. A Form 4 SEC filing detailed the purchase, indicating a positive sentiment.
Absci (NASDAQ:ABSI) Insider Acquires $229,000.00 in Stock
Absci Corporation insider Andreas Busch recently acquired 100,000 shares of the company's stock, totaling $229,000.00, increasing his direct ownership to 421,446 shares. This transaction, disclosed on Thursday, March 12th, boosted his position by over 31%. The article also details Absci's stock performance, institutional investor activity, and current analyst ratings.
Absci Corp chief innovation officer Busch buys $229,000 in stock
Absci Corp's Chief Innovation Officer, Andreas Busch, recently purchased 100,000 shares of common stock for $229,000. This insider buy comes as the stock trades near its 52-week low and is considered overvalued by InvestingPro. The company also announced strategic adjustments, including halting the internal advancement of its TL1A program and appointing a new Chief Medical Officer, leading to a downgrade from Morgan Stanley.
Absci (ABSI) CEO Sean McClain receives major equity grants and tax-share withholding
Absci Corp CEO Sean McClain was granted 406,200 Restricted Stock Units (RSUs) and a stock option for 1,603,200 shares on March 2, 2026. These equity grants are subject to three equal annual vesting installments beginning March 1, 2027, contingent on his continued service. Additionally, 25,316 shares were withheld on March 3, 2026, to cover tax obligations arising from RSU vesting, which was not a discretionary trade.
Absci (ABSI) Chief Innovation Officer has shares withheld for RSU tax obligations
Absci Corp's Chief Innovation Officer, Andreas Busch, had 1,257 shares of common stock, valued at $2.80 per share, withheld by the company to cover tax obligations arising from vesting restricted stock units on March 3, 2026. This transaction was an automatic tax-withholding and not a discretionary trade, reducing his directly held stake to 321,446 shares. An SEC Form 4 filing details this non-discretionary disposition.
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Absci Corporation announced that it granted a non-statutory stock option to Dr. Ransi Somaratne for 650,000 shares of its common stock as an inducement for his employment as Chief Medical Officer. This grant, approved by the Compensation Committee, has an exercise price of $2.57 per share and vests over four years. The company highlights its generative AI drug discovery platform and pipeline, including ABS-201 for hair regrowth and endometriosis.
Absci's Andreas Busch to Retire as Chief Innovation Officer, to Serve as Scientific Advisor
Absci announced that Andreas Busch will retire as Chief Innovation Officer on March 31, 2026, and will transition to a scientific advisor role starting April 3, 2026. His resignation is not due to any disagreement with the company. Busch will receive an annual cash retainer and stock options for his advisory services.
Absci Corporation Approves Inducement Grant for New Employees Under Nasdaq Rule 5635(c)(4)
Absci Corporation has approved an inducement grant for new employees, aligning with Nasdaq Listing Rule 5635(c)(4). This move by Absci's board of directors, announced on March 6, 2026, aims to attract and retain key personnel through stock options granted outside existing equity incentive plans. The grant complies with Nasdaq regulations allowing such awards for employment incentives without shareholder approval under specific conditions.
Absci Updates Leadership Indemnification Agreements Amid Governance Focus
Absci (ABSI) has updated its director and officer indemnification agreements to clarify protections and coverage, particularly for change-of-control events. This move aligns with the company's focus on its AI-driven drug pipeline and increasing regulatory complexities. Concurrently, Absci announced the retirement of CIO Andreas Busch and the appointment of Ransi Somaratne as Chief Medical Officer, signaling a strategic shift towards late-stage clinical execution for its AI-designed therapeutics.
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Absci Corporation announced it granted a non-statutory stock option to purchase 650,000 shares of its common stock to Dr. Ransi Somaratne in connection with his employment as Chief Medical Officer. The grant, approved by Absci's Compensation Committee, serves as an inducement to his employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $2.57 per share and vests over four years.
ARK Investment Management LLC Increases Stake in Absci Corporation $ABSI
ARK Investment Management LLC significantly increased its stake in Absci Corporation (NASDAQ:ABSI) by 21.1% in Q3, now owning about 8.13% of the company. Other institutional investors like Vanguard, Rhumbline Advisers, and Woodline Partners LP also boosted their holdings, bringing total institutional ownership to 52.05%. Despite a recent sale by the CEO, analysts maintain a "Moderate Buy" rating with a target price of $7.66 for the AI biotech company.
Absci Corp (ABSI) SVP awarded RSUs, options; shares withheld for taxes
Absci Corp's SVP, Todd Bedrick, reported changes in stock compensation, receiving 49,600 restricted stock units (RSUs) and a stock option for 195,900 shares. To cover taxes on the RSU award, 5,282 shares were withheld by the company at approximately $2.80 per share, which was not a discretionary trade. Both the RSUs and stock options will vest in substantially equal annual installments over three years, with the first vesting on March 1, 2027, contingent on his continuous service.
Absci strengthens clinical leadership with appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
Absci Corporation has announced the appointment of Ransi Somaratne, M.D., FACC, MBA, as its new Chief Medical Officer, strengthening its clinical leadership. This move comes as Absci, a data-first generative AI drug creation company, continues to develop its diversified portfolio of programs, focusing on cytokine biology and utilizing its Integrated Drug Creation platform. The company aims to accelerate time to clinic and increase the probability of success for biologics through AI and wet lab technologies.
Absci brings former Vertex leader to drive AI-designed therapeutics pipeline
Absci (Nasdaq: ABSI) has appointed Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer, effective March 3, 2026, to lead the clinical development of its AI-designed therapeutics, including the flagship ABS-201 program. Dr. Somaratne brings extensive experience from Vertex, BioMarin, and Amgen. Concurrently, Chief Innovation Officer Andreas Busch, Ph.D. will retire on March 31, 2026, transitioning to co-chair Absci’s Scientific Advisory Board.
Absci (ABSI) CFO has 8,307 shares withheld for RSU tax payment
Absci Corp's CFO/CBO, Zachariah Jonasson, had 8,307 common shares withheld by the company at $2.74 per share to cover tax obligations related to the vesting of Restricted Stock Units. This transaction, revealed in an SEC Form 4 filing on March 3, 2026, was not a discretionary sale. Following this event, Jonasson directly holds 375,231 shares of Absci.
Absci Corp. Forms Death Cross, Signaling Potential Bearish Trend Ahead
Absci Corp. has experienced a "Death Cross" technical event, where its short-term moving average dropped below its long-term average, signaling a potential bearish trend. The company has seen a significant one-year performance decline of 30.69%, contrasting with the S&P 500's gains. Technical indicators such as MACD, Bollinger Bands, KST, and Dow Theory all suggest a bearish outlook for Absci Corp., advising investor caution due to potential challenges ahead.
Absci Appoints Ransi Somaratne As Chief Medical Officer
Absci Corp. has announced the appointment of Ransi Somaratne, a former Vertex Pharmaceuticals executive, as its new Chief Medical Officer. Somaratne will lead the clinical development of Absci's AI-designed therapeutics pipeline. Concurrently, Chief Innovation Officer Andreas Busch will retire from his executive duties to co-chair the Scientific Advisory Board, continuing to provide strategic guidance.
ABSI Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive financial overview of Absci Corp (ABSI), detailing its income statement, balance sheet, and cash flow for both annual and quarterly periods ending September 30, 2025. It highlights key financial metrics such as declining revenue, negative profitability, strong liquidity but weak cash flow, and offers an overall financial health score. The analysis includes various ratios and answers frequently asked questions regarding the company's financial performance and position.
